该药物属于法尼酯 X 受体(Farnesoid X receptor，FXR)激动剂。FXR 是一种在肝脏和肠道中高水平表达的核受体，在胆酸代谢调节中起关键性作用。该药物是 ...

The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in ...

The Swiss pharma said it is to begin a phase IIb trial of one of its Farnesoid X receptor (FXR) agonists in combination with Allergan’s cenicriviroc in NASH. A group of around half a dozen ...

during which a panel of outside experts nearly unanimously voted against Intercept’s request for a full approval of its farnesoid X receptor agonist. During the meeting, 13 of the FDA’s ...

Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...

The FDA in 2016 granted accelerated approval to the FXR agonist as a second-line treatment for adults with PBC, either in ...